Source comparison
Cartalax vs Epithalon: Research Comparison
The following table summarizes the key distinguishing features of Cartalax vs Epithalon across structural, mechanistic, and practical research dimensions. Peptide sequence Ala-Glu-Asp (tripeptide) Ala-Glu-Asp-Gly (tetrapeptide) The single glycine residue deter
This comparison does not assign a generated winner or score.
- The following table summarizes the key distinguishing features of Cartalax vs Epithalon across structural, mechanistic, and practical research dimensions.
- Peptide sequence
- Ala-Glu-Asp (tripeptide)
- Ala-Glu-Asp-Gly (tetrapeptide)
- The single glycine residue determines tissue targeting. Not interchangeable
- Primary target tissue
- Cartilage, bone, connective tissue
- Pineal gland, CNS, somatic cells
- Cartalax for musculoskeletal, Epithalon for neuroendocrine and cellular aging
- Mechanism of action
- Chromatin binding, gene transcription (collagen II, aggrecan)
- Telomerase activation (TERT), melatonin regulation
- Distinct pathways with zero mechanistic overlap
- Plasma half-life
- 2.8–3.2 hours
- 6–8 hours (terminal phase)
- Cartalax requires twice-daily dosing; Epithalon allows once-daily
- Typical rodent dose
- 100–500 μg twice daily
- 50–100 μg once daily
- Dosing frequency differs due to pharmacokinetics
- Blood-brain barrier penetration
- No
- Yes
- Epithalon reaches CNS targets; Cartalax does not
- Observed endpoints
- Cartilage matrix synthesis, Mankin score improvement, collagen II expression
- Telomere length preservation, lifespan extension, circadian normalization
- Choose based on primary study endpoint
- Reconstituted stability (2–8°C)
- 14 days
- 14–21 days
- Both require refrigeration and single-use aliquots for maximum potency